Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On February 15, 2024, Sabre announced Q4 FY2023 financial results that missed analysts’ expectations. Additionally, the Company updated its revenue guidance and adjusted EBITDA outlook for Q1 and full year 2024 that was below analysts’ estimates. Analysts commenting on the lowered guidance noted the Company’s declining revenue over the last five years and its “large exposure” to the uncertainty of long-haul corporate travel in the industry.
Following this news, Sabre’s stock price fell by $0.99 per share, or approximately 22% to close at $3.42 per share.
| Ticker Symbol | Company Name | Join Deadline | Join |
|---|---|---|---|
| SUI | Sun Communities, Inc. | February 10, 2025 | Join |
| SAVA | Cassava Sciences, Inc. | February 10, 2025 | Join |
| APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
| BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
| PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
| NVO | Novo Nordisk A/S | March 25, 2025 | Join |
| GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
| NEM | Newmont Corporation | April 01, 2025 | Join |